Literature DB >> 11408184

Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists.

L Polevaya1, T Mavromoustakos, P Zoumboulakis, S Golic Grdadolnik, P Roumelioti, N Giatas, I Mutule, T Keivish, D V Vlahakos, E K Iliodromitis, D T Kremastinos, J Matsoukas.   

Abstract

The novel amide linked Angiotensin II (ANG II) cyclic analogue cyclo(3, 5) -[Sar(1)-Lys(3)-Glu(5)-Ile(8)] ANG II (18) has been designed, synthesized and bioassayed in anesthetized rabbits. The constrained cyclic analogue with a lactam amide bridge linking a Lys-Glu pair at positions 3 and 5 and possessing Ile at position 8, was synthesized by solution procedure using the maximum protection strategy. This analogue was found to be inhibitor of Angiotensin II. NMR spectroscopy coupled with computational analysis showed clustering between the side chains of the key aminoacids Tyr(4)-His(6)-Ile(8) similar to that observed with ANG II. The obtained data show that only pi*--pi* interactions observed in ANG II or its superagonist Sar(1) [ANG II] are missing. Therefore, it can be concluded that these interactions are essential for agonist activity. Conformational analysis comparisons between AT(1) antagonists losartan, eprosartan and irbesartan with C-terminal segment of cyclic compound 18 revealed structural similarities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408184     DOI: 10.1016/s0968-0896(01)00059-1

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT(1) angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies.

Authors:  George Agelis; Panagiota Roumelioti; Amalia Resvani; Serdar Durdagi; Maria-Eleni Androutsou; Konstantinos Kelaidonis; Demetrios Vlahakos; Thomas Mavromoustakos; John Matsoukas
Journal:  J Comput Aided Mol Des       Date:  2010-07-10       Impact factor: 3.686

Review 2.  A Global Review on Short Peptides: Frontiers and Perspectives.

Authors:  Vasso Apostolopoulos; Joanna Bojarska; Tsun-Thai Chai; Sherif Elnagdy; Krzysztof Kaczmarek; John Matsoukas; Roger New; Keykavous Parang; Octavio Paredes Lopez; Hamideh Parhiz; Conrad O Perera; Monica Pickholz; Milan Remko; Michele Saviano; Mariusz Skwarczynski; Yefeng Tang; Wojciech M Wolf; Taku Yoshiya; Janusz Zabrocki; Piotr Zielenkiewicz; Maha AlKhazindar; Vanessa Barriga; Konstantinos Kelaidonis; Elham Mousavinezhad Sarasia; Istvan Toth
Journal:  Molecules       Date:  2021-01-15       Impact factor: 4.411

Review 3.  From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy.

Authors:  John Matsoukas; Vasso Apostolopoulos; Anthony Zulli; Graham Moore; Konstantinos Kelaidonis; Kalliopi Moschovou; Thomas Mavromoustakos
Journal:  Molecules       Date:  2021-01-25       Impact factor: 4.411

4.  Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System.

Authors:  Graham J Moore; Harry Ridgway; Konstantinos Kelaidonis; Christos T Chasapis; Irene Ligielli; Thomas Mavromoustakos; Joanna Bojarska; John M Matsoukas
Journal:  Molecules       Date:  2022-07-29       Impact factor: 4.927

5.  Diminazene Aceturate Reduces Angiotensin II Constriction and Interacts with the Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  John M Matsoukas; Laura Kate Gadanec; Anthony Zulli; Vasso Apostolopoulos; Konstantinos Kelaidonis; Irene Ligielli; Kalliopi Moschovou; Nikitas Georgiou; Panagiotis Plotas; Christos T Chasapis; Graham Moore; Harry Ridgway; Thomas Mavromoustakos
Journal:  Biomedicines       Date:  2022-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.